Last updated: 2026-09-10 16:27:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Moleculin Biotech, Inc. (MBRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.81, with a market capitalization of $14.61M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.16 to $15.75. This page covers its latest market performance, valuation, price trends and company information.
$14.61M | |
$0.79 | |
$22,027.50 | |
$0.16 | |
$0.77 | |
290.22K | |
1.27M | |
-- | |
$15.75 | |
$0.16 | |
-- | |
-- |
Moleculin Biotech, Inc. (MBRX) is currently trading at $0.81 as of 2026-09-10 16:24:00, up 6.14% ($0.05) from the previous close of $0.77
During today's regular trading session, MBRX has traded between $0.16 and $22,027.50, with a trading volume of 290.22K shares. The current price is near the lower end of today's range.
Over the past seven days, Moleculin Biotech, Inc. (MBRX) moved from $0.64 to $0.81, representing a gain of 25.95% ($0.17).
The stock traded between $0.62 and $0.82 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 462.95 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.2%
MBRX is currently trading at $0.81, placing it 4.2% of the way from its 52-week low of $0.16 to its 52-week high of $15.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Moleculin Biotech, Inc. (MBRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.